Huadong Medicine stock reports 2.53 percent profit growth

Published on 10/05/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Huadong Medicine stock was last at CNY 27.69 on September 30, 2026, after a 3.13 percent daily gain. First-half revenue reached RMB 22.067 billion.

Huadong Med, CNE0000011S1, Illustration mit AI erstellt.

Huadong Medicine (ISIN CNE0000011S1) reported RMB 22.067 billion in first-half 2026 revenue, up 1.81 percent year over year, while its stock was last at CNY 27.69 on the Shenzhen Stock Exchange on September 30, 2026, up 3.13 percent. The results give investors two clear signals: overall growth remains measured, while newer pharmaceutical products are expanding faster.

Revenue rises 1.81 percent

According to Stockstar in the report dated August 27, 2026, net profit attributable to shareholders reached RMB 1.861 billion in the six months ended June 30, 2026, an increase of 2.53 percent from the same period a year earlier. Adjusted net profit excluding non-recurring items rose 5.44 percent to RMB 1.858 billion.

The earnings mix was more important than the headline revenue increase. Pharmaceutical distribution generated RMB 14.182 billion in first-half revenue, up 1.68 percent, while the segment's net profit reached RMB 233 million, an increase of 3.02 percent, according to Stockstar.

Innovation outpaces the group

Huadong Medicine's innovative product sales and agency revenue increased 52 percent to RMB 1.684 billion in the first half of 2026, accounting for 21.14 percent of pharmaceutical industry revenue including CSO business. That contrast makes the product pipeline the central growth variable: the core pharmaceutical industry segment grew 8.92 percent to RMB 7.969 billion, while distribution remained a steadier, lower-growth base.

The report also shows a clear counterweight in aesthetic medicine. Segment revenue fell 41.43 percent to RMB 651 million in the first half, reflecting pressure in domestic and overseas consumer markets, according to Stockstar. Separately, VCBeat Health reported on September 29, 2026, that the MC2-01 topical cream achieved its primary endpoint in a Phase III trial for plaque psoriasis.

Stock trades 36.8 percent below high

Huadong Medicine stock was last at CNY 27.69 on September 30, 2026, at 3:04 p.m. CST, with volume of 32,858,967 shares. The price stood 36.8 percent below the 52-week high of CNY 43.78 and above the 52-week low of CNY 25.63, while market capitalization was CNY 48.6 billion on the same date.